



Review

Improving access to tuberculosis preventive therapy and treatment for children



Ben J. Marais*

The Children's Hospital at Westmead and the Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI), Sydney Medical School, University of Sydney, Locked Bag 4001, Sydney, New South Wales, 2145, Australia

ARTICLE INFO

Article history:

Received 11 October 2016

Received in revised form 7 December 2016

Accepted 7 December 2016

Corresponding Editor: Eskild Petersen, Aarhus, Denmark.

Keywords:

Tuberculosis

Children

Drug-resistant

SUMMARY

Children suffer a huge burden of disease in tuberculosis (TB) endemic countries. This disease burden was largely invisible when TB control programmes focused exclusively on adults with sputum smear-positive disease. High-level advocacy and better data have improved visibility, but the establishment of functional paediatric TB programmes remains challenging. The key issues that limit children's access to TB preventive therapy and treatment in endemic areas are briefly discussed. Barriers to preventive therapy include (1) the perceived inability to rule out active disease, (2) fear of creating drug resistance, (3) non-implementation of existing guidelines in the absence of adequate monitoring, and (4) poor adherence with long preventive therapy courses. Barriers to TB treatment include (1) perceived diagnostic difficulties, (2) non-availability of chest radiography, (3) young children presenting to unprepared maternal and child health (MCH) services, and (4) the absence of child-friendly formulations. With drug-resistant disease there is currently no guidance on the use of preventive therapy and treatment is usually restricted to cases with bacteriologically confirmed disease, which excludes most young children from care, even if their likely source case has documented drug-resistant TB.

© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Although the World Health Organization (WHO) launched the ambitious End TB Strategy in 2015,¹ tuberculosis (TB) remains the leading infectious cause of death worldwide. The WHO estimates that 10.4 million people developed TB in 2014, of whom 580 000 had multidrug-resistant (MDR) or rifampicin-monoresistant TB.² The huge disease burden suffered by children in TB endemic countries was rarely appreciated in the past,³ but this has changed with high-level advocacy and better data to improve visibility.^{4–6} Recently the United Nations Secretary-General's Special Envoy on TB Dr Eric Goosby stated: "For far too long, children with tuberculosis (TB) have remained in the shadows. While there have been tremendous strides made in improving other areas of child health and survival, we have yet to see the parallel advances in pediatric TB. Instead, many children with TB die before they can be diagnosed and treated".⁴ The WHO estimates that one million

children developed TB in 2015, resulting in 210 000 deaths.^{2,7} At least 5000 children were likely to have died from multidrug-resistant TB and around 40 000 were co-infected with HIV.^{7,8}

In the absence of routine drug susceptibility testing (DST), MDR-TB estimates are highly variable and the number of affected children often underappreciated.^{7,8} This mainly results from the fact that the level of primary MDR-TB transmission within endemic communities is grossly underestimated when extrapolated from the MDR-TB rate observed among new TB cases only. In reality, the majority of MDR-TB diagnosed among retreatment cases also represents primary transmission.^{9–11} Children dying from TB, including drug-resistant disease, are often incorrectly classified as pneumonia, meningitis, HIV/AIDS, or malnutrition deaths.¹² Of the estimated 921 000 (95% confidence interval 812 000–1 117 000) pneumonia deaths that occurred in children under 5 years of age in 2015, most occurred among young children living in TB endemic areas.¹³ In these settings, TB is likely to be a substantial cause and comorbidity of childhood pneumonia.¹⁴ Autopsy studies suggest that TB is a major contributor to under-5 mortality in Sub-Saharan Africa, irrespective of the child's HIV status,^{15,16} and the same is likely to apply in other settings with uncontrolled TB transmission.

* Tel.: +61 3 93454788; fax: +61 3 93456667.

E-mail address: ben.marais@health.nsw.gov.au

TB is an important preventable cause of under-5 mortality, since children respond well to treatment if they are able to access care.

2. Barriers to treatment access

High-level advocacy is essential, but it needs to be sustained and amplified at national and local levels to support effective implementation strategies. Few TB endemic countries have adequate strategies or resources allocated to implement TB prevention and care programmes for children. The WHO Roadmap for Childhood TB also emphasizes the need for better linkage and integration with maternal and child health (MCH) initiatives.¹⁷ In some countries, significant progress has been made with child TB action plans jointly developed by national TB programmes (NTPs), local paediatric societies, and MCH programmes.¹⁸ In response to the Roadmap's call for better linkages, the United Nations Children's Fund (UNICEF) recently organized a consultation meeting on childhood TB integration in New York, exploring how best to strengthen community and primary health systems.¹⁹ Table 1 summarizes key barriers that continue to limit children's access to TB preventive therapy and treatment.²⁰

2.1. Preventive therapy

The most effective means to prevent TB infection (and subsequent disease) in children is to improve epidemic control.²¹ However, in settings with ongoing TB transmission, efforts to prevent TB disease are necessary to reduce TB-related morbidity and mortality in the most vulnerable.²² The WHO and the International Union Against TB and Lung Disease (The Union) advise preventive therapy for all immunocompromised children and those less than 5 years of age (irrespective of their immune status) following proven TB infection or close contact with an infectious TB case.²³ Although this is rarely implemented in TB endemic settings and massive policy–practice gaps remain,²⁴ the creation of a latent TB infection (LTBI) taskforce and publication of evidence-based LTBI guidelines in 2015²⁵ demonstrates the commitment of the WHO to improve the delivery of preventive therapy to young and vulnerable children.

2.1.1. Perceived inability to rule out active disease

A major concern of health care workers in resource-limited settings is their perceived inability to rule out TB disease with certainty, given the impression that a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) and chest radiograph are required for adequate screening. However, symptom-based screening offers a safe and feasible alternative,^{26–28} and is recommended by the WHO for contact screening in resource-limited settings.²³ Chest radiography has little value in completely asymptomatic children^{27,29} and should not act as a barrier to the provision of preventive therapy in high-risk contacts. Detailed diagnostic work-up should be reserved for the minority of contacts with persistent symptoms suggestive of TB.^{23,27}

2.1.2. Fear of creating drug resistance

The exclusion of TB disease is important, since inadvertent treatment of active disease with one or two drugs used in preventive therapy could select for drug resistance. Fear of selecting drug-resistant strains that will be transmitted within the community is the most frequently cited reason why health care workers and countries are reluctant to implement preventive therapy strategies.^{20,24} The risk of acquiring drug resistance is greatest in patients with high organism loads and generally low if international screening guidelines are adhered to.^{30,31} It is conceivable that the selective pressure imposed by population-wide preventive therapy will be substantial, even though no elevated risk of drug resistance has been observed among those receiving TB preventive therapy in small-scale studies of limited duration.³² However, the use of preventive therapy in young children is associated with minimal risk, as they tend to develop paucibacillary disease and rarely transmit the infection.³³ Therefore fear of creating drug resistance within the community is irrelevant and should not compromise the provision of preventive therapy to young children.

2.1.3. Non-implementation of existing guidelines

Despite the sound scientific basis underlying current recommendations and the drafting of international and national recommendations, contact screening is rarely implemented in

Table 1
Barriers identified and solutions proposed to improve TB preventive therapy and treatment access for children

Barriers identified	Solutions proposed
<i>General</i>	
Lack of awareness at the local programmatic level	Persistent high-level advocacy, amplified at the national and local levels
Inadequate training	Inclusion of childhood TB in medical and nursing training curricula, including MCH training programmes
<i>Preventive therapy</i>	
Perceived inability to screen	Symptom-based screening adequate
Fear of creating drug resistance	Minimal risk in children (education)
Poor implementation of guidelines	Adequate monitoring and evaluation
Poor adherence with prolonged isoniazid preventive therapy (IPT)	Develop child-friendly short-course formulations; e.g., isoniazid/rifapentine combination tablet
<i>Treatment for disease</i>	
Diagnostic difficulties and poor laboratory infrastructure	Most cases can be diagnosed accurately using a systematic approach; expand access to Xpert MTB/RIF and/or culture
Non-availability of high quality chest radiographs	Improve availability and interpretation of high quality digital chest radiographs
Young children presenting to unprepared MCH programmes	MCH programmes should include training on childhood TB and embrace TB service delivery in endemic settings
Non-availability of quality assured child-friendly formulations	Ensure that new GDF-approved child-friendly formulations are widely available
<i>Drug-resistant disease</i>	
No guidance on preventive therapy	Provide interim guidance on preventive therapy for drug-resistant TB exposure; support research
Poor access to diagnosis and treatment	Expand access to Xpert MTB/RIF and/or culture; treat according to DST of most likely source case
No child-friendly formulations	Use creative administration methods – children do tolerate most second-line drugs and achieve excellent treatment outcomes; ensure that all new TB drugs have a paediatric development plan

TB, tuberculosis; MCH, maternal and child health; GDF, global drug facility; DST, drug susceptibility testing.

Download English Version:

<https://daneshyari.com/en/article/5667572>

Download Persian Version:

<https://daneshyari.com/article/5667572>

[Daneshyari.com](https://daneshyari.com)